Screener
UroGen Pharma URGN Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Other current liabilities | — | 62 |
| Lease liabilities | (113) | (1,344) |
| Restricted deposit | (1) | (1) |
| Net cash used in operating activities | (78,322) | (81,849) |
| Cash Flows From Investing Activities | ||
| Purchases of marketable securities | (24,780) | (68,140) |
| Maturities of marketable securities | 5,879 | 70,768 |
| Purchases of property and equipment | (114) | (185) |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's operating cash flow?
- UroGen Pharma (URGN) reported operating cash flow of -$33.01M in Q2 2026.
- How has UroGen Pharma's operating cash flow changed year-over-year?
- UroGen Pharma's operating cash flow increased by 17.1% year-over-year, from -$39.83M to -$33.01M.
- What is the long-term trend for UroGen Pharma's operating cash flow?
- Over 4 years (2021 to 2025), UroGen Pharma's operating cash flow has grown at a 17.6% compound annual growth rate (CAGR), from -$84.89M to -$162.44M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about UroGen Pharma's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude